

Indian Journal of Pharmaceutical Sciences

Scientific Publication of the Indian Pharmaceutical Association

Indexed in Ind MED, EMBASE/Excerpta Medica, International Pharmaceutical Abstracts, Chemical Abstracts.

Volume 69

Number 5

September-October 2007

CONTENTS

REVIEW ARTICLES

- Recent Trends in Drug-Likeness Prediction: A Comprehensive Review of *In Silico* Methods**
R. U. KADAM AND N. ROY 609-615
- Biodegradable Polymers: Which, When and Why?**
V. B. KOTWAL, MARIA SAIFEE, NAZMA INAMDAR AND KIRAN BHISE 616-625

RESEARCH PAPERS

- Strong Cation Exchange Resin for Improving Physicochemical Properties and Sustaining Release of Ranitidine Hydrochloride**
S. KHAN, A. GUHA, P. G. YEOLE, AND P. KATARIYA 626-632
- Novel Co-Processed Excipients of Mannitol and Microcrystalline Cellulose for Preparing Fast Dissolving Tablets of Glipizide**
S. JACOB, A. A. SHIRWAIKAR, A. JOSEPH, K. K. SRINIVASAN 633-639
- Formulation and Optimization of Directly Compressible Isoniazid Modified Release Matrix Tablet**
M. C. GOHEL, R. K. PARIKH, M. N. PADSHALA, K. G. SARVAIYA AND D. G. JENA 640-645
- Effect of Casting Solvent and Polymer on Permeability of Propranolol Hydrochloride Through Membrane Controlled Transdermal Drug Delivery System**
T. E. G. K. MURTHY AND V. S. KISHORE 646-650
- Preparation of Mucoadhesive Microspheres for Nasal Delivery by Spray Drying**
MAHALAXMI RATHANANAND, D. S. KUMAR, A. SHIRWAIKAR, RAVI KUMAR, D. SAMPATH KUMAR AND R. S. PRASAD 651-657
- Effect of Polymers on Crystallo-co-agglomeration of Ibuprofen-Paracetamol: Factorial Design**
A. PAWAR, A. R. PARADKAR, S. S. KADAM AND K. R. MAHADIK 658-664
- Synthesis and Antimicrobial Evaluation of Some Novel 2-Imino-3-(4'-carboxamido pyridyl)-5-Arylidene-4-Thiazolidinones and their Brominated Derivatives**
P. MISHRA, T. LUKOSE AND S. K. KASHAW 665-668
- Measurement of Urine and Plasma Oxalate with Reusable Strip of Amaranthus Leaf Oxalate Oxidase**
NISHA SHARMA, MINAKSHI SHARMA, V. KUMAR AND C. S. PUNDIR 669-673

SHORT COMMUNICATIONS

- Simultaneous HPLC Estimation of Omeprazole and Domperidone from Tablets**
LAKSHMI SIVASUBRAMANIAN AND V. ANILKUMAR 674-676
- Isolation and Evaluation of Fenugreek Seed Husk as a Granulating Agent**
AMELIA AVACHAT, K. N. GUJAR, V. B. KOTWAL AND SONALI PATIL 676-679
- Synthesis and *In Vitro* Efficacy of some Halogenated Imine Derivatives as Potential Antimicrobial Agents**
A. K. HALVE, DEEPTI BHADAURIA, B. BHASKAR, R. DUBEY AND VASUDHA SHARMA 680-682
- Simultaneous Spectrophotometric Estimation of Atorvastatin Calcium and Ezetimibe in Tablets**
S. S. SONAWANE, A. A. SHIRKHEDKAR, R. A. FURSULE AND S. J. SURANA 683-684
- High Performance Thin Layer Chromatographic Estimation of Lansoprazole and Domperidone in Tablets**
J. V. SUSHEEL, M. LEKHA AND T. K. RAVI 684-686
- Antimicrobial Activity of *Helicteres isora* Root**
S. VENKATESH, K. SAILAXMI, B. MADHAVA REDDY AND MULLANGI RAMESH 687-689
- Synthesis and Antibacterial Activity of 2-phenyl-3,5-diphenyl (substituted) -6-aryl-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d]thiazoles**
S. K. SAHU, S. K. MISHRA, R. K. MOHANTA, P. K. PANDA AND MD. AFZAL AZAM 689-692

- Simultaneous Estimation of Aceclofenac, Paracetamol and Chlorzoxazone in Tablets**
G. GARG, SWARNLATA SARAF AND S. SARAF 692-694
- Reverse Phase High Performance Liquid Chromatography Method for Estimation of Ezetimibe in Bulk and Pharmaceutical Formulations**
S. K. AKMAR, LATA KOTHAPALLI, ASHA THOMAS, SUMITRA JANGAM AND A. D. DESHPANDE 695-697
- Synthesis and Antiinflammatory Activity of N-Aryl Anthranilic Acid and its Derivatives**
J. K. JOSHI, V. R. PATEL, K. PATEL, D. RANA, K. SHAH, RONAK PATEL AND RAJESH PATEL 697-699
- RP-HPLC Method for the Determination of Atorvastatin calcium and Nicotinic acid in Combined Tablet Dosage Form**
D. A. SHAH, K. K. BHATT, R. S. MEHTA, M. B. SHANKAR AND S. L. BALDANIA 700-703
- Determination of Etoricoxib in Pharmaceutical Formulations by HPLC Method**
H. M. PATEL, B. N. SUHAGIA, S. A. SHAH AND I. S. RATHOD 703-705

Proceedings of the Symposium on Advances in Pulmonary and Nasal Drug Delivery, October 2007, Mumbai

- Albumin Microspheres of Fluticasone Propionate Inclusion Complexes for Pulmonary Delivery**
A. A. LOHADE, D. J. SINGH, J. J. PARMAR, D. D. HEGDE, M. D. MENON, P. S. SONI, A. SAMAD AND R. V. GAIKWAD 707-709
- Design and Development of Thermoreversible Mucoadhesive Microemulsion for Intranasal Delivery of Sumatriptan Succinate**
R. S. BHANUSHALI AND A. N. BAJAJ 709-712
- Preparation and Characterization of Chitosan Nanoparticles for Nose to Brain Delivery of a Cholinesterase inhibitor**
BHAVNA, V. SHARMA, M. ALI, S. BABOOTA AND J. ALI 712-713
- Poloxamer Coated Fluticasone Propionate Microparticles for Pulmonary Delivery; *In Vivo* Lung Deposition and Efficacy Studies**
D. J. SINGH, J. J. PARMAR, D. D. HEGDE, M. D. MENON, P. S. SONI, A. SAMAD, AND R. V. GAIKWAD 714-715
- Sustained Release Budesonide Liposomes: Lung Deposition and Efficacy Evaluation**
J. J. PARMAR, D. J. SINGH, D. D. HEGDE, M. D. MENON, P. S. SONI, A. SAMAD AND R. V. GAIKWAD 716-717
- Generation of Budesonide Microparticles by Spray Drying Technology for Pulmonary Delivery**
S. R. NAIKWADE AND A. N. BAJAJ 717-721
- Microemulsion of Lamotrigine for Nasal Delivery**
A. J. SHENDE, R. R. PATIL AND P. V. DEVARAJAN 721-722
- Development of a pMDI Formulation Containing Budesonide**
E. ROBINS, G. BROUET AND S. PRIOLKAR 722-724
- Development of a pMDI Formulation Containing Salbutamol**
E. ROBINS, G. WILLIAMS AND S. PRIOLKAR 724-726
- Aqua Triggered *In Situ* Gelling Microemulsion for Nasal Delivery**
R. R. SHELKE AND P. V. DEVARAJAN 726-727
- In vivo* Performance of Nasal Spray Pumps in Human Volunteers By SPECT-CT Imaging**
S. A. HAZARE, M. D. MENON, P. S. SONI, G. WILLIAMS AND G. BROUET 728-729
- Nasal Permeation Enhancement of Sumatriptan Succinate through Nasal Mucosa**
S. S. SHIDHAYE, N. S. SAINDANE, P. V. THAKKAR, S. B. SUTAR AND V. J. KADAM 729-731
- Formulation Development of Eucalyptus Oil Microemulsion for Intranasal Delivery**
N. G. TIWARI AND A. N. BAJAJ 731-733

Sustained Release Budesonide Liposomes: Lung Deposition and Efficacy Evaluation

J. J. PARMAR*, D. J. SINGH, D. D. HEGDE, M. D. MENON, P. S. SONI¹, A. SAMAD² AND R. V. GAIKWAD²

Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Mumbai - 400 098, India, ¹Board of Radiation and Isotope Technology and Medical Cyclotron Facility, Mumbai - 400 012, India, ²Department of Medicine, Bombay Veterinary College, Mumbai - 400 012, India

Budesonide (BDS) is a corticosteroid used in the prophylactic management of asthma. However, frequent dosing and adverse effects (local and systemic) remain a major concern in the use of BDS¹. A reduction in the frequency of dosing would be convenient, especially for chronic asthma. Liposomal systems for sustained pulmonary drug delivery have been particularly attractive because of their compatibility with lung surfactant components². The present study aimed to evaluate the pulmonary deposition and *in vivo* efficacy of sustained release aerosolized budesonide liposomal systems for improved therapy of asthma.

MATERIALS AND METHODS

Liposomes were prepared by lipid film hydration method³ and freeze dried using trehalose as cryoprotectant (Lebconco, England). The liposomes were characterized for entrapment efficiency, particle size, and surface topography by ESEM, *in vitro* drug release in simulated lung fluid at 37⁰ at pH 7.4. The respirable or fine particle fraction (FPF) was determined by using twin stage impinger (TSI). The liposomes were radiolabeled with technetium (^{99m}Tc) using SnCl₂ as reducing agent. Rabbit, placed in a head only exposure chamber was allowed to inhale the nebulized spray of the labeled liposomes for 10 min. Scintigraphic images of rabbit lungs were recorded by a Gamma camera (Millenium MPS System) at periodic intervals and analyzed. *In vivo* acute toxicity of liposomes was evaluated in mice by intratracheal administration. *In vivo* efficacy of BDS liposomes was evaluated by histamine induced bronchoconstriction in guinea pigs.

RESULTS AND DISCUSSION

Liposomes were obtained as porous cake after freeze

drying with narrow particle size distribution (3-7 μm). Freeze dried liposomes appeared as aggregated particles with lipids on the surface (fig. 1). Dynamic formation of liposomes was monitored by placing a drop of saline on the freeze dried liposomes; spherical structures were clearly seen and after two minutes liposomes were completely formed (figs. 2) The drug release was sustained for more than 70 h for all batches and FPF was found to be in the range of 19-26% based on emitted dose. In the *in vivo* deposition studies, only about 8-10% of delivered dose was found to be deposited in lungs. The major fraction was localized in peripheral region, due to fine particle nature of the nebulized droplets. The activity was




Fig. 1: ESEM photomicrograph of freeze dried liposomes




Fig. 2: ESEM photomicrograph of hydration of freeze dried liposomes
The photograph on the left shows liposomes at time zero and the photograph on the right indicates complete hydration at two minutes

*For correspondence

E-mail: jayeshparmar@yahoo.com




Fig. 3: Gamma scintigraphy images after administration of technetium labeled liposomes of BDS
Lung scans were taken at different time points after administration of technetium labeled liposomes of BDS to New Zealand White rabbits




Fig. 4: ■■■ represent control, free drug and liposome respectively

localized in the lungs for up to 12 h in comparison to 6 mins for free ^{99m}Tc , indicating prolonged retention of the BDS liposomes in lungs (fig. 3). *In vivo* acute toxicity study indicated the safety of budesonide loaded liposomes. In the *in vivo* efficacy studies, recovery time after histamine challenge significantly reduced in liposome treated guinea pigs at all time points confirming the sustained action of liposomal BDS (fig. 4). In conclusion, this investigation led to the development of stable freeze dried liposomal

systems for pulmonary delivery of budesonide. With this system, it was possible to obtain localized sustained action of drugs in lungs with marked reduction in toxic effects associated with the drug.

ACKNOWLEDGEMENTS

The authors wish to thank BRNS (sanction No.2004/35/5/BRNS) for financial assistance, Cipla for budesonide and Natterman GmbH for lipids.

REFERENCES

- O'Connell EJ. Review of the unique properties of Budesonide. Clin Ther 2003;25:C42-53.
- Schreier H, Ricardo J, Gonzalez-Rothi, Arlene AS. Pulmonary delivery of liposomes. J Control Release 1993;24:223-9.
- Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52.